

Imbruvica® (ibrutinib) – New formulation approval

- On February 16, 2018, the FDA approved Pharmacyclic's <u>Imbruvica (ibrutinib)</u> tablets, which shares the same indications as Imbruvica <u>capsules</u>.
- Imbruvica is approved in adult patients for the following indications:
 - Treatment of mantle cell lymphoma (MCL) who have received at least one prior therapy
 - Treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)
 - Treatment of CLL/SLL with 17p deletion
 - Treatment of Waldenström's macroglobulinemia (WM)
 - Treatment of marginal zone lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD20-based therapy
 - Treatment of chronic graft-versus-host disease (cGVHD) after failure of one or more lines of systemic therapy
- The approval of Imbruvica tablets was based on the efficacy and safety data of Imbruvica capsules.
- Warnings and precautions of Imbruvica include hemorrhage, infections, cytopenias, cardiac arrhythmias, hypertension, second primary malignancies, tumor lysis syndrome, and embryo fetal toxicity.
- The most common adverse reactions (≥ 20%) with Imbruvica use in patients with B-cell malignancies (MCL, CLL/SLL, WM and MZL) were neutropenia, thrombocytopenia, diarrhea, anemia, musculoskeletal pain, rash, nausea, bruising, fatigue, hemorrhage, and pyrexia.
- The most common adverse reactions (≥ 20%) with Imbruvica use in patients with cGVHD were fatigue, bruising, diarrhea, thrombocytopenia, muscle spasms, stomatitis, nausea, hemorrhage, anemia, and pneumonia.
- The recommended dosage of Imbruvica varies by specific indication.
 - In MCL and MZL patients, the recommended dosage of Imbruvica is 560 mg orally once daily.
 - In CLL/SLL, WM, and cGVHD patients, the recommended dosage of Imbruvica is 420 mg orally once daily.
 - Do not open, break, or chew the capsules. Do not cut, crush, or chew the tablets.
- Janssen's launch plans for Imbruvica tablets are pending. Imbruvica will be available as 140 mg, 280 mg, 420 mg, and 560 mg tablets.



optumrx.com

OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at **optum.com**.

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2018 Optum, Inc. All rights reserved.